{
  "items": "50",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More",
      "url": "https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-moonlake-immunotherapeuticsmltx-urged-to-join-class-action--contact-the-gross-law-firm-to-learn-more-302640529.html",
      "time_published": "20251220T080906",
      "authors": [
        "NULL"
      ],
      "summary": "The Gross Law Firm is urging shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) who incurred losses during the class period of March 10, 2024, to September 29, 2025, to join a class action lawsuit. The complaint alleges that the company made false or misleading statements regarding its sole drug candidate, SLK, particularly its purported superiority over BIMZELX. Shareholders have until December 15, 2025, to register as lead plaintiff.",
      "banner_image": "https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg?w=300",
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.907446"
        },
        {
          "topic": "finance",
          "relevance_score": "0.735554"
        }
      ],
      "overall_sentiment_score": -0.703861,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.708819",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MLTX SHAREHOLDER NEWS: Did MoonLake Immunotherapeutics Mislead Investors? Contact BFA Law about the Ongoing Securities Class Action by December 15 Deadline",
      "url": "https://www.abc27.com/business/press-releases/accesswire/1115733/mltx-shareholder-news-did-moonlake-immunotherapeutics-mislead-investors-contact-bfa-law-about-the-ongoing-securities-class-action-by-december-15-deadline",
      "time_published": "20251218T090906",
      "authors": [],
      "summary": "Bleichmar Fonti & Auld LLP has filed a securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) and its executives. The lawsuit alleges that MoonLake misled investors regarding the efficacy of its drug sonelokimab, leading to a significant stock price drop after disappointing Phase 3 trial results. Investors who purchased MoonLake common stock have until December 15, 2025, to seek appointment as lead plaintiff in the case.",
      "banner_image": "https://i0.wp.com/www.abc27.com/wp-content/uploads/sites/55/2025/07/4B93DBB72B28C420050747F227A42B63-e1753137253361.jpg?w=2000&ssl=1",
      "source": "ABC27",
      "category_within_source": "General",
      "source_domain": "ABC27",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944325"
        },
        {
          "topic": "finance",
          "relevance_score": "0.723686"
        }
      ],
      "overall_sentiment_score": -0.93777,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.945937",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025 - Contact Levi & Korsinsky",
      "url": "https://www.cbs42.com/business/press-releases/accesswire/1117642/lost-money-on-moonlake-immunotherapeutics-mltx-join-class-action-before-december-15-2025-contact-levi-korsinsky",
      "time_published": "20251216T100831",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX) on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The lawsuit alleges that the company made false statements regarding its drug candidate, SLK, and its purported superiority to monoclonal antibodies. Shareholders affected are encouraged to contact Levi & Korsinsky for information on potential recovery.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117642",
      "source": "CBS 42",
      "category_within_source": "General",
      "source_domain": "CBS 42",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.949422"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.814532"
        }
      ],
      "overall_sentiment_score": -0.43633,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.441228",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025",
      "url": "https://www.abc4.com/business/press-releases/accesswire/1117913/join-class-action-to-recover-losses-from-moonlake-immunotherapeutics-mltx-contact-levi-korsinsky-before-december-15-2025",
      "time_published": "20251216T100831",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against MoonLake Immunotherapeutics (MLTX) on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The lawsuit alleges that MoonLake made false statements and concealed information regarding its drug candidate, SLK, specifically concerning its purported superiority over BIMZELX. Investors affected are encouraged to contact Levi & Korsinsky to explore potential recovery under federal securities laws before December 15, 2025.",
      "banner_image": "https://www.nxsttv.com/wp-content/uploads/2022/08/ANW_COLOR_FULL_VECTOR.png?w=300",
      "source": "ABC4 Utah",
      "category_within_source": "General",
      "source_domain": "ABC4 Utah",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916517"
        },
        {
          "topic": "finance",
          "relevance_score": "0.745047"
        }
      ],
      "overall_sentiment_score": -0.443648,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.405925",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors",
      "url": "https://www.cbs42.com/business/press-releases/globenewswire/9602279/portnoy-law-firm-announces-class-action-on-behalf-of-moonlake-immunotherapeutics-inc-investors",
      "time_published": "20251216T100831",
      "authors": [
        "Portnoy Law"
      ],
      "summary": "The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX). The lawsuit alleges that MoonLake made misleading statements regarding its sole drug candidate, sonelokimab (SLK), developed for hidradenitis suppurativa (HS), particularly concerning its efficacy compared to a competing drug. Investors who purchased securities between March 10, 2024, and September 29, 2025, have until December 15, 2025, to file a lead plaintiff motion.",
      "banner_image": "NULL",
      "source": "CBS 42",
      "category_within_source": "General",
      "source_domain": "CBS 42",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909567"
        },
        {
          "topic": "finance",
          "relevance_score": "0.707229"
        }
      ],
      "overall_sentiment_score": -0.500991,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.506077",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More",
      "url": "https://www.news10.com/business/press-releases/cision/20251215NY45807/shareholders-that-lost-money-on-moonlake-immunotherapeuticsmltx-urged-to-join-class-action-contact-the-gross-law-firm-to-learn-more",
      "time_published": "20251216T100831",
      "authors": [
        "NULL"
      ],
      "summary": "The Gross Law Firm is urging shareholders who lost money on MoonLake Immunotherapeutics (NASDAQ: MLTX) shares purchased between March 10, 2024, and September 29, 2025, to join a class action lawsuit. The lawsuit alleges that MoonLake Immunotherapeutics made misleading statements regarding its drug candidate SLK, specifically concerning its purported superiority over BIMZELX and its clinical efficacy. Shareholders have until December 15, 2025, to register as a lead plaintiff.",
      "banner_image": "https://www.nxsttv.com/wp-content/uploads/2021/11/prn_cision_logo_desktop.png",
      "source": "NEWS10 ABC",
      "category_within_source": "General",
      "source_domain": "NEWS10 ABC",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923500"
        },
        {
          "topic": "finance",
          "relevance_score": "0.835139"
        }
      ],
      "overall_sentiment_score": -0.735787,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.748268",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors",
      "url": "https://www.8newsnow.com/business/press-releases/globenewswire/9602279/portnoy-law-firm-announces-class-action-on-behalf-of-moonlake-immunotherapeutics-inc-investors",
      "time_published": "20251216T091001",
      "authors": [
        "Portnoy Law"
      ],
      "summary": "The Portnoy Law Firm has announced a class action lawsuit on behalf of investors of MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX). The lawsuit covers individuals who purchased MoonLake securities between March 10, 2024, and September 29, 2025. Investors have until December 15, 2025, to file a lead plaintiff motion to recover losses related to alleged corporate wrongdoing concerning the efficacy claims of MoonLake's sole drug candidate, sonelokimab.",
      "banner_image": "https://ml.globenewswire.com/media/ea0dd9c0-6e41-4d5a-ad27-b277677af6df/small/portnoylaw-logohighresroundlogoonly-jpg.jpg",
      "source": "KLAS 8 News Now",
      "category_within_source": "General",
      "source_domain": "KLAS 8 News Now",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913691"
        },
        {
          "topic": "finance",
          "relevance_score": "0.737335"
        }
      ],
      "overall_sentiment_score": -0.443773,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.404293",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025",
      "url": "https://fox59.com/business/press-releases/accesswire/1117913/join-class-action-to-recover-losses-from-moonlake-immunotherapeutics-mltx-contact-levi-korsinsky-before-december-15-2025",
      "time_published": "20251216T091001",
      "authors": [],
      "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX) on behalf of investors who suffered losses due to alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made false statements and concealed information regarding the clinical superiority and efficacy of its drug candidate, SLK. Investors are encouraged to contact Levi & Korsinsky for information on how to recover their losses before December 15, 2025.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117913",
      "source": "Fox 59",
      "category_within_source": "General",
      "source_domain": "Fox 59",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.938802"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.806714"
        }
      ],
      "overall_sentiment_score": -0.826671,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.829706",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "New SueWallSt Podcast Covers MoonLake Immunotherapeutics (MLTX) Class Action",
      "url": "https://fox40.com/business/press-releases/accesswire/1117417/new-suewallst-podcast-covers-moonlake-immunotherapeutics-mltx-class-action",
      "time_published": "20251216T090920",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP has released a podcast detailing a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX). The lawsuit alleges securities fraud occurred between March 10, 2024, and September 29, 2025, where the company made false statements regarding its drug candidate SLK's superiority to monoclonal antibodies. Investors who lost money due to these alleged actions are encouraged to contact Levi & Korsinsky.",
      "banner_image": "https://nxstrib.com/wp-content/uploads/2022/10/ANW_COLOR_FULL_VECTOR.png?w=300",
      "source": "FOX40 News",
      "category_within_source": "General",
      "source_domain": "FOX40 News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915088"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.815708"
        }
      ],
      "overall_sentiment_score": -0.643127,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.642227",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "New SueWallSt Podcast Covers MoonLake Immunotherapeutics (MLTX) Class Action",
      "url": "https://www.abc4.com/business/press-releases/accesswire/1117417/new-suewallst-podcast-covers-moonlake-immunotherapeutics-mltx-class-action",
      "time_published": "20251216T090920",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP has released a new SueWallSt Podcast discussing a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX). The lawsuit alleges securities fraud occurred between March 10, 2024, and September 29, 2025, claiming the company made false statements regarding the purported superiority of its drug candidate, SLK. Investors who suffered losses and have questions about the class action are encouraged to contact Levi & Korsinsky.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117417",
      "source": "ABC4 Utah",
      "category_within_source": "General",
      "source_domain": "ABC4 Utah",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.919239"
        }
      ],
      "overall_sentiment_score": -0.624816,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.641299",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025 - Contact Levi & Korsinsky",
      "url": "https://www.wjbf.com/business/press-releases/accesswire/1117642/lost-money-on-moonlake-immunotherapeutics-mltx-join-class-action-before-december-15-2025-contact-levi-korsinsky",
      "time_published": "20251216T090920",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky LLP has filed a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) on behalf of shareholders who suffered losses between March 10, 2024, and September 29, 2025. The lawsuit alleges that MoonLake made false statements regarding the superiority of its drug candidate, SLK, compared to BIMZELX. Affected shareholders are encouraged to contact Levi & Korsinsky by December 15, 2025, to learn about their rights to potential recovery.",
      "banner_image": "https://i0.wp.com/www.wjbf.com/wp-content/uploads/sites/47/2025/12/agent.jpg?w=2000&ssl=1",
      "source": "WJBF",
      "category_within_source": "General",
      "source_domain": "WJBF",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.940640"
        },
        {
          "topic": "finance",
          "relevance_score": "0.829842"
        }
      ],
      "overall_sentiment_score": -0.739851,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.736034",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More",
      "url": "https://www.wlns.com/business/press-releases/cision/20251215NY45807/shareholders-that-lost-money-on-moonlake-immunotherapeuticsmltx-urged-to-join-class-action-contact-the-gross-law-firm-to-learn-more",
      "time_published": "20251216T090920",
      "authors": [],
      "summary": "The Gross Law Firm is urging shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) who incurred losses from March 10, 2024, to September 29, 2025, to join a class action lawsuit. The lawsuit alleges that MoonLake made misleading statements regarding its drug candidate, SLK, particularly its supposed superiority over BIMZELX and its clinical efficacy. Shareholders have until December 15, 2025, to register for potential lead plaintiff appointment.",
      "banner_image": "https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg?p=publish",
      "source": "WLNS 6 News",
      "category_within_source": "General",
      "source_domain": "WLNS 6 News",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.834671"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.720660"
        }
      ],
      "overall_sentiment_score": -0.616567,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.645416",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More",
      "url": "https://ktla.com/business/press-releases/cision/20251215NY45807/shareholders-that-lost-money-on-moonlake-immunotherapeuticsmltx-urged-to-join-class-action-contact-the-gross-law-firm-to-learn-more",
      "time_published": "20251216T090920",
      "authors": [
        "NULL"
      ],
      "summary": "The Gross Law Firm has issued a notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) who incurred losses during the class period of March 10, 2024, to September 29, 2025. The firm is encouraging these shareholders to join a class action lawsuit due to allegations of false and misleading statements made by the company regarding its drug candidate, SLK, and its purported superiority. The deadline to register as a lead plaintiff in this class action is December 15, 2025.",
      "banner_image": "https://i0.wp.com/ktla.com/wp-content/uploads/sites/4/2025/12/A421ABF74245DAD301CCAA9EE50B27E9.jpg?w=2000&ssl=1",
      "source": "KTLA",
      "category_within_source": "General",
      "source_domain": "KTLA",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925077"
        },
        {
          "topic": "finance",
          "relevance_score": "0.704877"
        }
      ],
      "overall_sentiment_score": -0.62124,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.632039",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MLTX CLASS ACTION: MoonLake Immunotherapeutics Sued for Securities Fraud after 90% Stock Drop - Investors Urged to Contact BFA Law before December 15 Deadline",
      "url": "https://www.cbs42.com/business/press-releases/accesswire/1116176/mltx-class-action-moonlake-immunotherapeutics-sued-for-securities-fraud-after-90-stock-drop-investors-urged-to-contact-bfa-law-before-december-15-deadline",
      "time_published": "20251216T090856",
      "authors": [
        "NULL"
      ],
      "summary": "A class-action lawsuit has been filed against MoonLake Immunotherapeutics and its executives for alleged securities fraud, following a nearly 90% stock drop after disappointing Phase 3 VELA trial results for sonelokimab. Investors who purchased MoonLake stock are encouraged to contact Bleichmar Fonti & Auld LLP by December 15, 2025, to explore legal options and potentially lead the case. The lawsuit claims that the company misrepresented the superiority and commercial viability of its drug, SLK, causing significant financial losses to investors when the truth was revealed.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/1bd96818-0407-47ff-8368-1ca698db05d3/1116176/image.png",
      "source": "CBS 42",
      "category_within_source": "General",
      "source_domain": "CBS 42",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930747"
        },
        {
          "topic": "finance",
          "relevance_score": "0.844956"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.716675"
        }
      ],
      "overall_sentiment_score": -0.428415,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.437718",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "New SueWallSt Podcast Covers MoonLake Immunotherapeutics (MLTX) Class Action",
      "url": "https://www.wjtv.com/business/press-releases/accesswire/1117417/new-suewallst-podcast-covers-moonlake-immunotherapeutics-mltx-class-action",
      "time_published": "20251216T090846",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP has released a podcast regarding a class action securities lawsuit against MoonLake Immunotherapeutics. The lawsuit alleges that the company made false statements and concealed information about its sole drug candidate, SLK, specifically concerning its purported superiority over BIMZELX and its clinical efficacy. Investors who lost money between March 10, 2024, and September 29, 2025, are affected.",
      "banner_image": "https://i0.wp.com/www.wjtv.com/wp-content/uploads/sites/72/2025/12/d42fd938352741a58754f8a2c03e454a-e1694209414415.jpg?w=2000&ssl=1",
      "source": "WJTV",
      "category_within_source": "General",
      "source_domain": "WJTV",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.909354"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.823539"
        }
      ],
      "overall_sentiment_score": -0.640027,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.645942",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025",
      "url": "https://fox40.com/business/press-releases/accesswire/1117913/join-class-action-to-recover-losses-from-moonlake-immunotherapeutics-mltx-contact-levi-korsinsky-before-december-15-2025",
      "time_published": "20251216T000912",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP has announced a securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX). The lawsuit aims to recover losses for investors who purchased MLTX securities between March 10, 2024, and September 29, 2025, due to alleged false statements concerning the company's sole drug candidate, SLK, and its purported superiority. Investors are encouraged to contact Levi & Korsinsky before December 15, 2025, to explore potential recovery options.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117913",
      "source": "FOX40 News",
      "category_within_source": "General",
      "source_domain": "FOX40 News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.908715"
        },
        {
          "topic": "finance",
          "relevance_score": "0.713415"
        }
      ],
      "overall_sentiment_score": -0.414547,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.447532",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025",
      "url": "https://www.kark.com/business/press-releases/accesswire/1117913/join-class-action-to-recover-losses-from-moonlake-immunotherapeutics-mltx-contact-levi-korsinsky-before-december-15-2025",
      "time_published": "20251215T200912",
      "authors": [],
      "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX) on behalf of investors who suffered losses due to alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made false statements regarding its drug candidate, SLK, and its purported superiority to monoclonal antibodies. Investors who purchased MLTX securities during this period are encouraged to contact Levi & Korsinsky before December 15, 2025, to explore their recovery options.",
      "banner_image": "https://www.kark.com/wp-content/uploads/sites/85/2025/10/kark-login-dialog-modal.webp?w=263",
      "source": "KARK",
      "category_within_source": "General",
      "source_domain": "KARK",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.935099"
        },
        {
          "topic": "finance",
          "relevance_score": "0.733134"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.602722"
        }
      ],
      "overall_sentiment_score": -0.609799,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.634310",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More",
      "url": "https://www.sahmcapital.com/news/content/shareholders-that-lost-money-on-moonlake-immunotherapeuticsmltx-urged-to-join-class-action-contact-the-gross-law-firm-to-learn-more-2025-12-15",
      "time_published": "20251215T170000",
      "authors": [
        "NULL"
      ],
      "summary": "The Gross Law Firm is notifying shareholders of MoonLake Immunotherapeutics (MLTX) who purchased shares between March 10, 2024, and September 29, 2025, about a class action lawsuit. The complaint alleges that MoonLake made misleading statements regarding its drug candidate SLK's superiority over BIMZELX. Shareholders are urged to register by December 15, 2025, to potentially become lead plaintiffs in the case.",
      "banner_image": "https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.829206"
        }
      ],
      "overall_sentiment_score": -0.438823,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.404736",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Contact Levi & Korsinsky by December 15, 2025 Deadline to Join Class Action Against MoonLake Immunotherapeutics(MLTX)",
      "url": "https://www.globenewswire.com/news-release/2025/12/15/3205809/3080/en/Contact-Levi-Korsinsky-by-December-15-2025-Deadline-to-Join-Class-Action-Against-MoonLake-Immunotherapeutics-MLTX.html",
      "time_published": "20251215T154900",
      "authors": [],
      "summary": "Levi & Korsinsky, LLP is notifying investors in MoonLake Immunotherapeutics (MLTX) of a class action securities lawsuit. The lawsuit alleges that MoonLake made false statements regarding its drug candidate, SLK, between March 10, 2024, and September 29, 2025. Investors who suffered losses have until December 15, 2025, to request to be appointed as lead plaintiff.",
      "banner_image": "https://ml.globenewswire.com/media/MWJkYWI2ODItNzcxYi00MTlkLWI5OTYtOWI2MzdlOWQ0OGU5LTEwMzIyOTMtMjAyNS0xMi0xNS1lbg==/tiny/Levi-Korsinsky-LLP.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.924946"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.826500"
        }
      ],
      "overall_sentiment_score": -0.620161,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "0.949291",
          "ticker_sentiment_score": "-0.633346",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm",
      "url": "https://www.businesswire.com/news/home/20251215837738/en/MLTX-Investors-Have-Opportunity-to-Lead-MoonLake-Immunotherapeutics-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm",
      "time_published": "20251215T140912",
      "authors": [
        "NULL"
      ],
      "summary": "The Schall Law Firm is reminding investors of MoonLake Immunotherapeutics (MLTX) about a class action lawsuit for securities fraud. The lawsuit alleges that MoonLake made false and misleading statements regarding its drug candidate, sonelokimab (SLK), claiming its superiority without proven advantages. Investors who purchased securities between March 10, 2024, and September 29, 2025, and suffered losses are encouraged to contact the firm before December 15, 2025.",
      "banner_image": "https://mms.businesswire.com/media/20251215837738/en/827144/4/Schall-Firm-Logo-640x360.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.911783"
        },
        {
          "topic": "finance",
          "relevance_score": "0.836341"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.734270"
        }
      ],
      "overall_sentiment_score": -0.44099,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.423885",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More",
      "url": "https://www.wjbf.com/business/press-releases/cision/20251215NY45807/shareholders-that-lost-money-on-moonlake-immunotherapeuticsmltx-urged-to-join-class-action-contact-the-gross-law-firm-to-learn-more",
      "time_published": "20251215T140912",
      "authors": [
        "The Gross Law Firm"
      ],
      "summary": "The Gross Law Firm is notifying shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) who incurred losses during the period of March 10, 2024, to September 29, 2025, about a class action lawsuit. The complaint alleges that the company made misleading statements regarding its drug candidate, SLK, particularly its purported superiority over BIMZELX. Shareholders are encouraged to contact the firm to potentially be appointed lead plaintiff and register for the class action before the December 15, 2025, deadline.",
      "banner_image": "https://i0.wp.com/www.wjbf.com/wp-content/uploads/sites/47/2025/12/C582699E9D707DCDE104FC4E20D09D0C.jpg?w=2000&ssl=1",
      "source": "WJBF",
      "category_within_source": "General",
      "source_domain": "WJBF",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.888512"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.800542"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.773475"
        }
      ],
      "overall_sentiment_score": -0.621367,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.645919",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025 - Contact Levi & Korsinsky",
      "url": "https://www.news10.com/business/press-releases/accesswire/1117642/lost-money-on-moonlake-immunotherapeutics-mltx-join-class-action-before-december-15-2025-contact-levi-korsinsky",
      "time_published": "20251215T134500",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX) seeking to recover losses for shareholders who were adversely affected by alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit alleges that MoonLake made false statements and/or concealed information about the efficacy and superiority of its drug candidate, SLK, compared to BIMZELX. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky to learn about their rights to seek recovery by December 15, 2025.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117642",
      "source": "NEWS10 ABC",
      "category_within_source": "General",
      "source_domain": "NEWS10 ABC",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909973"
        },
        {
          "topic": "finance",
          "relevance_score": "0.733904"
        }
      ],
      "overall_sentiment_score": -0.600921,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.648778",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "New SueWallSt Podcast Covers MoonLake Immunotherapeutics (MLTX) Class Action",
      "url": "https://www.8newsnow.com/business/press-releases/accesswire/1117417/new-suewallst-podcast-covers-moonlake-immunotherapeutics-mltx-class-action",
      "time_published": "20251215T130912",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP has released a new podcast detailing a class action securities lawsuit filed against MoonLake Immunotherapeutics (NASDAQ: MLTX). The lawsuit alleges MoonLake made false statements regarding its drug candidate, SLK, specifically about its superiority over competitor BIMZELX due to similar molecular targets and SLK's Nanobody structure not conferring superior clinical benefits or translating to clinical efficacy. Investors who lost money between March 10, 2024, and September 29, 2025, are affected.",
      "banner_image": "https://i0.wp.com/www.8newsnow.com/wp-content/uploads/sites/59/2025/12/snapshot-2025-12-15T224840.489.jpg?w=2000&ssl=1",
      "source": "KLAS 8 News Now",
      "category_within_source": "General",
      "source_domain": "KLAS 8 News Now",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.926573"
        },
        {
          "topic": "finance",
          "relevance_score": "0.832401"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.731648"
        }
      ],
      "overall_sentiment_score": -0.612889,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.645331",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm",
      "url": "https://www.globenewswire.com/news-release/2025/12/15/3205615/0/en/MOONLAKE-DECEMBER-15th-DEADLINE-Bragar-Eagel-Squire-P-C-Urgently-Reminds-MoonLake-Immunotherapeutics-Investors-to-Contact-the-Firm.html",
      "time_published": "20251215T104600",
      "authors": [],
      "summary": "Bragar Eagel & Squire, P.C. has filed a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) on behalf of investors who purchased stock between March 10, 2024, and September 29, 2025. The lawsuit alleges that MoonLake misled investors about the efficacy of its drug candidate, sonelokimab (SLK), which failed to outperform a competitor, leading to a nearly 90% stock collapse. Investors have until December 15, 2025, to apply to be appointed as lead plaintiff.",
      "banner_image": "https://ml.globenewswire.com/media/ZDg4MmViZGUtOGRlOS00Nzk1LTlhOGMtNzBkM2U0MmRkZDA1LTExMTE5NjktMjAyNS0xMi0xNS1lbg==/tiny/Bragar-Eagel-Squire.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.838141"
        }
      ],
      "overall_sentiment_score": -0.916511,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.916499",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors",
      "url": "https://www.wane.com/business/press-releases/globenewswire/9602279/portnoy-law-firm-announces-class-action-on-behalf-of-moonlake-immunotherapeutics-inc-investors",
      "time_published": "20251215T102000",
      "authors": [
        "NULL"
      ],
      "summary": "The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX). Investors who purchased securities between March 10, 2024, and September 29, 2025, are encouraged to contact the firm to discuss their legal rights, with a deadline to file a lead plaintiff motion by December 15, 2025. The complaint alleges that MoonLake's sole drug candidate, sonelokimab, failed to demonstrate comparable or superior efficacy to Union Chimique Belge\u2019s BIMZELX for hidradenitis suppurativa, impacting its commercial prospects.",
      "banner_image": "https://ml.globenewswire.com/media/ea0dd9c0-6e41-4d5a-ad27-b277677af6df/small/portnoylaw-logohighresroundlogoonly-jpg.jpg",
      "source": "WANE 15",
      "category_within_source": "General",
      "source_domain": "WANE 15",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.821224"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.904782"
        }
      ],
      "overall_sentiment_score": -0.615561,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.642758",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors",
      "url": "https://www.globenewswire.com/news-release/2025/12/15/3205593/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-Moonlake-Immunotherapeutics-Inc-Investors.html",
      "time_published": "20251215T102000",
      "authors": [
        "NULL"
      ],
      "summary": "The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX). The lawsuit covers securities purchased between March 10, 2024, and September 29, 2025, and alleges corporate wrongdoing concerning MoonLake's sole drug candidate, sonelokimab (SLK), for hidradenitis suppurativa. Investors have until December 15, 2025, to file a lead plaintiff motion.",
      "banner_image": "https://ml.globenewswire.com/media/OWFlMTE1MTItZjVhYy00MjY4LWEzMWQtZmQ2ZWU2MDgzNzUwLTEyMDcwODAtMjAyNS0xMi0xNS1lbg==/tiny/Portnoy-Law.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.926656"
        },
        {
          "topic": "finance",
          "relevance_score": "0.709265"
        }
      ],
      "overall_sentiment_score": -0.416354,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.418801",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Levi & Korsinsky Notifies MoonLake Immunotherapeutics (MLTX) Shareholders of Class Action Lawsuit and December 15, 2025 Deadline",
      "url": "https://www.yourcentralvalley.com/business/press-releases/accesswire/1117260/levi-korsinsky-notifies-moonlake-immunotherapeutics-mltx-shareholders-of-class-action-lawsuit-and-december-15-2025-deadline",
      "time_published": "20251215T100831",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky has announced a class action lawsuit against MoonLake Immunotherapeutics (MLTX), seeking to recover losses for shareholders affected by alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that MoonLake made false statements regarding its sole drug candidate, SLK, specifically concerning its molecular targets, nanobody structure, and purported superiority to monoclonal antibodies. Shareholders have until December 15, 2025, to learn about their rights to seek recovery.",
      "banner_image": "https://i0.wp.com/www.yourcentralvalley.com/wp-content/uploads/sites/54/2025/12/image_7c1b6c.png?w=2000&ssl=1",
      "source": "yourcentralvalley.com",
      "category_within_source": "General",
      "source_domain": "yourcentralvalley.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.946994"
        }
      ],
      "overall_sentiment_score": -0.422791,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.401765",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Class Action Lawsuit Filed: MoonLake Immunotherapeutics (MLTX) - Join by December 15, 2025 - Contact Levi & Korsinsky",
      "url": "https://ktla.com/business/press-releases/accesswire/1117457/class-action-lawsuit-filed-moonlake-immunotherapeutics-mltx-join-by-december-15-2025-contact-levi-korsinsky",
      "time_published": "20251215T095900",
      "authors": [],
      "summary": "A class action lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) alleging securities fraud due to misleading statements about its drug candidate, SLK. Shareholders who suffered losses between March 10, 2024, and September 29, 2025, are encouraged to join by December 15, 2025, by contacting Levi & Korsinsky, LLP. The lawsuit claims SLK's purported superiority over BIMZELX was misrepresented.",
      "banner_image": "https://i0.wp.com/ktla.com/wp-content/uploads/sites/4/2025/04/GettyImages-2192600780.jpg?w=2000&ssl=1",
      "source": "KTLA",
      "category_within_source": "General",
      "source_domain": "KTLA",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928797"
        },
        {
          "topic": "finance",
          "relevance_score": "0.825062"
        }
      ],
      "overall_sentiment_score": -0.710262,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.710566",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MoonLake Immunotherapeutics (MLTX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 15, 2025 Deadline",
      "url": "https://www.mypanhandle.com/business/press-releases/accesswire/1117375/moonlake-immunotherapeutics-mltx-class-action-lawsuit-levi-korsinsky-reminds-investors-of-december-15-2025-deadline",
      "time_published": "20251215T090933",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky reminds investors of the December 15, 2025 deadline to join a class action lawsuit against MoonLake Immunotherapeutics (MLTX). The lawsuit alleges that the company made false statements regarding its drug candidate, SLK, specifically concerning its purported superiority over BIMZELX. Investors who suffered losses between March 10, 2024, and September 29, 2025, are encouraged to learn about their rights to recover losses.",
      "banner_image": "https://i0.wp.com/www.mypanhandle.com/wp-content/uploads/sites/88/2025/12/693f99b55526f3.00897017.jpeg?w=2000&ssl=1",
      "source": "mypanhandle.com",
      "category_within_source": "General",
      "source_domain": "mypanhandle.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.910305"
        },
        {
          "topic": "finance",
          "relevance_score": "0.801838"
        }
      ],
      "overall_sentiment_score": -0.845355,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.802984",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Class Action Lawsuit Filed: MoonLake Immunotherapeutics (MLTX) - Join by December 15, 2025 - Contact Levi & Korsinsky",
      "url": "https://www.wcia.com/business/press-releases/accesswire/1117457/class-action-lawsuit-filed-moonlake-immunotherapeutics-mltx-join-by-december-15-2025-contact-levi-korsinsky",
      "time_published": "20251215T090920",
      "authors": [
        "NULL"
      ],
      "summary": "A class action lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ:MLTX) alleging securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made false statements about its drug candidate SLK's superiority over BIMZELX, despite both sharing molecular targets. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky by December 15, 2025, to learn about their recovery rights.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117457",
      "source": "WCIA.com",
      "category_within_source": "General",
      "source_domain": "WCIA.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900794"
        },
        {
          "topic": "finance",
          "relevance_score": "0.739934"
        }
      ],
      "overall_sentiment_score": -0.832387,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.841769",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More",
      "url": "https://www.counton2.com/business/press-releases/cision/20251215NY45807/shareholders-that-lost-money-on-moonlake-immunotherapeuticsmltx-urged-to-join-class-action-contact-the-gross-law-firm-to-learn-more",
      "time_published": "20251215T090000",
      "authors": [
        "NULL"
      ],
      "summary": "The Gross Law Firm is urging shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) who incurred losses during the class period of March 10, 2024, to September 29, 2025, to join a class action lawsuit. The complaint alleges that the company made misleading statements regarding the purported superiority of its drug candidate, SLK, over BIMZELX. Shareholders have until December 15, 2025, to register as lead plaintiff.",
      "banner_image": "https://i0.wp.com/www.counton2.com/wp-content/uploads/sites/7/2025/12/CID-WEB.jpg?w=2000&ssl=1",
      "source": "WCBD",
      "category_within_source": "General",
      "source_domain": "WCBD",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933782"
        },
        {
          "topic": "finance",
          "relevance_score": "0.715034"
        }
      ],
      "overall_sentiment_score": -0.8138,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.813542",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Pomerantz LLP Reminds Investors: Securities Lawsuit Has Been Filed Against MoonLake Immunotherapeutics \u2013 MLTX",
      "url": "https://fox59.com/business/press-releases/accesswire/1095340/pomerantz-llp-reminds-investors-securities-lawsuit-has-been-filed-against-moonlake-immunotherapeutics-mltx/",
      "time_published": "20251215T010933",
      "authors": [
        "NULL"
      ],
      "summary": "Pomerantz LLP has announced that a class action lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) on behalf of investors. The lawsuit alleges securities fraud following disappointing Phase 3 VELA trial results for sonelokimab, which caused a significant drop in MoonLake's stock price. Investors who purchased MoonLake securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1095340",
      "source": "Fox 59",
      "category_within_source": "General",
      "source_domain": "Fox 59",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943445"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.817162"
        }
      ],
      "overall_sentiment_score": -0.808936,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.831181",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Levi & Korsinsky Notifies MoonLake Immunotherapeutics (MLTX) Shareholders of Class Action Lawsuit and December 15, 2025 Deadline",
      "url": "https://fox4kc.com/business/press-releases/accesswire/1117260/levi-korsinsky-notifies-moonlake-immunotherapeutics-mltx-shareholders-of-class-action-lawsuit-and-december-15-2025-deadline",
      "time_published": "20251214T104700",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX) on behalf of shareholders who experienced losses due to alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made false statements about its drug candidate SLK's superiority and tissue penetration compared to BIMZELX. Shareholders who suffered losses are encouraged to seek information about their rights, with a deadline to participate set for December 15, 2025.",
      "banner_image": "NULL",
      "source": "FOX4KC.com",
      "category_within_source": "General",
      "source_domain": "FOX4KC.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.934050"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.820891"
        }
      ],
      "overall_sentiment_score": -0.712851,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.732709",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Levi & Korsinsky Notifies MoonLake Immunotherapeutics (MLTX) Shareholders of Class Action Lawsuit and December 15, 2025 Deadline",
      "url": "https://www.wboy.com/business/press-releases/accesswire/1117260/levi-korsinsky-notifies-moonlake-immunotherapeutics-mltx-shareholders-of-class-action-lawsuit-and-december-15-2025-deadline",
      "time_published": "20251214T100831",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky has announced a class action securities lawsuit against MoonLake Immunotherapeutics (MLTX) for shareholders who suffered losses due to alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit alleges that MoonLake made false statements regarding the superiority of its drug candidate, SLK, compared to BIMZELX. Affected shareholders have until December 15, 2025, to learn about their rights to recovery.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117260",
      "source": "WBOY.com",
      "category_within_source": "General",
      "source_domain": "WBOY.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.836998"
        },
        {
          "topic": "finance",
          "relevance_score": "0.711396"
        }
      ],
      "overall_sentiment_score": -0.726503,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.719085",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Class Action Lawsuit Alert: Levi & Korsinsky Reminds MoonLake Immunotherapeutics (MLTX) Investors of December 15, 2025 Deadline",
      "url": "https://www.wjbf.com/business/press-releases/accesswire/1117222/class-action-lawsuit-alert-levi-korsinsky-reminds-moonlake-immunotherapeutics-mltx-investors-of-december-15-2025-deadline",
      "time_published": "20251214T090920",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky LLP has alerted investors of MoonLake Immunotherapeutics (NASDAQ:MLTX) about a class action lawsuit with a deadline of December 15, 2025. The lawsuit seeks to recover losses for shareholders affected by alleged securities fraud between March 10, 2024, and September 29, 2025. The core allegations are that the company made false statements regarding its drug candidate SLK's purported superiority over BIMZELX, given their shared molecular targets and the structural differences not leading to a clinical benefit.",
      "banner_image": "https://i0.wp.com/www.wjbf.com/wp-content/uploads/sites/47/2025/12/agent.jpg?w=2000&ssl=1",
      "source": "WJBF",
      "category_within_source": "General",
      "source_domain": "WJBF",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.946670"
        },
        {
          "topic": "finance",
          "relevance_score": "0.740965"
        }
      ],
      "overall_sentiment_score": -0.747401,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.732519",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Class Action Lawsuit Alert: Levi & Korsinsky Reminds MoonLake Immunotherapeutics (MLTX) Investors of December 15, 2025 Deadline",
      "url": "https://cw33.com/business/press-releases/accesswire/1117222/class-action-lawsuit-alert-levi-korsinsky-reminds-moonlake-immunotherapeutics-mltx-investors-of-december-15-2025-deadline",
      "time_published": "20251214T000912",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky LLP reminds investors of MoonLake Immunotherapeutics (MLTX) about the December 15, 2025, deadline to join a class action lawsuit. This lawsuit seeks to recover losses for shareholders who were negatively affected by alleged securities fraud between March 10, 2024, and September 29, 2025. The complaint alleges that MoonLake Immunotherapeutics made false statements regarding the superiority and clinical efficacy of its sole drug candidate, SLK.",
      "banner_image": "https://i0.wp.com/cw33.com/wp-content/uploads/sites/8/2025/12/Photo-Dec-11-2025-10-07-12-AM-1.jpg?w=2000&ssl=1",
      "source": "CW33.com",
      "category_within_source": "General",
      "source_domain": "CW33.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933541"
        },
        {
          "topic": "finance",
          "relevance_score": "0.702095"
        }
      ],
      "overall_sentiment_score": -0.421405,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.443878",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MoonLake Immunotherapeutics Class Action: Levi & Korsinsky Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX",
      "url": "https://www.morningstar.com/news/pr-newswire/20251212ny45116/moonlake-immunotherapeutics-class-action-levi-korsinsky-reminds-moonlake-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-december-15-2025-mltx",
      "time_published": "20251213T110912",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP reminds investors of MoonLake Immunotherapeutics (NASDAQ: MLTX) about a class action lawsuit with a lead plaintiff deadline of December 15, 2025. The lawsuit alleges that MoonLake made false statements and concealed information about its drug candidate, SLK, specifically regarding its clinical benefits and superiority to existing treatments. Investors who suffered losses between March 10, 2024, and September 29, 2025, are encouraged to participate.",
      "banner_image": "https://www.morningstar.com/assets/img/morningstar.d826858.svg",
      "source": "Morningstar",
      "category_within_source": "General",
      "source_domain": "Morningstar",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.942732"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.713182"
        }
      ],
      "overall_sentiment_score": -0.636755,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.633293",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Pomerantz LLP Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics \u2013 MLTX",
      "url": "https://fox59.com/business/press-releases/accesswire/1095338/pomerantz-llp-reminds-investors-with-losses-on-their-investment-in-moonlake-immunotherapeutics-mltx",
      "time_published": "20251213T100933",
      "authors": [
        "NULL"
      ],
      "summary": "Pomerantz LLP has filed a class action lawsuit against MoonLake Immunotherapeutics (MLTX) following disappointing Phase 3 VELA trial results that caused a significant stock price drop. Investors who purchased MoonLake securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff. The lawsuit alleges securities fraud or other unlawful business practices by MoonLake's officers and/or directors.",
      "banner_image": "NULL",
      "source": "Fox 59",
      "category_within_source": "General",
      "source_domain": "Fox 59",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.919385"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.833612"
        }
      ],
      "overall_sentiment_score": -0.814673,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.836015",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MLTX COURT ALERT: MoonLake Immunotherapeutics Securities Fraud Class Action is Ongoing - Investors with Losses Alerted to Contact BFA Law by December 15",
      "url": "https://fox59.com/business/press-releases/accesswire/1116186/mltx-court-alert-moonlake-immunotherapeutics-securities-fraud-class-action-is-ongoing-investors-with-losses-alerted-to-contact-bfa-law-by-december-15",
      "time_published": "20251213T100933",
      "authors": [
        "NULL"
      ],
      "summary": "A securities class action lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ:MLTX) and its executives for alleged violations of federal securities laws. The lawsuit claims that the company misrepresented the clinical benefits of its investigational drug, sonelokimab, which led to a significant stock price drop following disappointing Phase 3 trial results. Investors who suffered losses are encouraged to contact Bleichmar Fonti & Auld LLP by December 15, 2025, to join the lawsuit.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1116186",
      "source": "Fox 59",
      "category_within_source": "General",
      "source_domain": "Fox 59",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934695"
        },
        {
          "topic": "finance",
          "relevance_score": "0.729871"
        }
      ],
      "overall_sentiment_score": -0.729499,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.743796",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C.",
      "url": "https://www.globenewswire.com/news-release/2025/12/13/3204988/0/en/MOONLAKE-CLASS-ACTION-DEADLINE-Bragar-Eagel-Squire-P-C-Urgently-Reminds-MoonLake-Immunotherapeutics-Investors-to-Contact-the-Firm-Before-December-15th.html",
      "time_published": "20251213T092100",
      "authors": [],
      "summary": "Bragar Eagel & Squire, P.C. has filed a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ:MLTX) on behalf of investors who purchased shares between March 10, 2024, and September 29, 2025. The lawsuit alleges MoonLake misled investors about its drug candidate sonelokimab (SLK), which was promoted as superior to competitors but failed to achieve statistical significance in a Phase 3 trial, leading to an 89.9% stock collapse. Investors have until December 15, 2025, to apply to be appointed as lead plaintiff.",
      "banner_image": "https://ml.globenewswire.com/media/MWI2MTRjMzAtNmZmMC00YzMxLThhMTQtYTAwNjNlNjQyNGRiLTExMTE5NjktMjAyNS0xMi0xMy1lbg==/tiny/Bragar-Eagel-Squire.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944271"
        },
        {
          "topic": "finance",
          "relevance_score": "0.704367"
        }
      ],
      "overall_sentiment_score": -0.830687,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.801312",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C.",
      "url": "https://www.globenewswire.com/news-release/2025/12/13/3204988/0/en/moonlake-class-action-deadline-bragar-eagel-squire-p-c-urgently-reminds-moonlake-immunotherapeutics-investors-to-contact-the-firm-before-december-15th.html",
      "time_published": "20251213T092100",
      "authors": [],
      "summary": "Bragar Eagel & Squire, P.C. has filed a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) on behalf of investors who purchased stock between March 10, 2024, and September 29, 2025. The lawsuit alleges that MoonLake misled investors about its drug candidate sonelokimab (SLK), which failed to show superiority over a competitor and led to an 89.9% stock decline. Investors have until December 15, 2025, to apply to be a lead plaintiff.",
      "banner_image": "https://ml.globenewswire.com/media/MWI2MTRjMzAtNmZmMC00YzMxLThhMTQtYTAwNjNlNjQyNGRiLTExMTE5NjktMjAyNS0xMi0xMy1lbg==/tiny/Bragar-Eagel-Squire.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.926550"
        }
      ],
      "overall_sentiment_score": -0.837998,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.801824",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (MLTX) - Recover Losses - Contact Levi & Korsinsky Before December 15, 2025",
      "url": "https://ktla.com/business/press-releases/accesswire/1112852/class-action-lawsuit-filed-against-moonlake-immunotherapeutics-mltx-recover-losses-contact-levi-korsinsky-before-december-15-2025",
      "time_published": "20251213T080951",
      "authors": [
        "NULL"
      ],
      "summary": "A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) alleging securities fraud, stemming from alleged false statements and concealment regarding their drug candidate, SLK. Shareholders who suffered losses between March 10, 2024, and September 29, 2025, are encouraged to contact Levi & Korsinsky LLP to learn about potential recovery options before December 15, 2025. The lawsuit claims that the company misrepresented SLK's clinical benefits and superiority over existing monoclonal antibodies.",
      "banner_image": "https://i0.wp.com/ktla.com/wp-content/uploads/sites/4/2024/02/AP24017576707178-e1707085954197.jpg?w=2000&ssl=1",
      "source": "KTLA",
      "category_within_source": "General",
      "source_domain": "KTLA",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925404"
        },
        {
          "topic": "finance",
          "relevance_score": "0.816885"
        }
      ],
      "overall_sentiment_score": -0.422768,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.388699",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MoonLake Immunotherapeutics (MLTX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 15, 2025 Deadline",
      "url": "https://www.ksnt.com/business/press-releases/accesswire/1117375/moonlake-immunotherapeutics-mltx-class-action-lawsuit-levi-korsinsky-reminds-investors-of-december-15-2025-deadline",
      "time_published": "20251213T080906",
      "authors": [],
      "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) to recover losses for shareholders affected by alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made false statements regarding the superiority of its drug candidate, SLK, over BIMZELX. Investors who suffered losses are encouraged to learn about their rights to seek recovery by the December 15, 2025 deadline.",
      "banner_image": "https://i0.wp.com/www.ksnt.com/wp-content/uploads/sites/86/2025/12/694f909551e206.57024475.jpeg?w=2000&ssl=1",
      "source": "KSNT 27 News",
      "category_within_source": "General",
      "source_domain": "KSNT 27 News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943280"
        },
        {
          "topic": "finance",
          "relevance_score": "0.749200"
        }
      ],
      "overall_sentiment_score": -0.710756,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.724167",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics Securities Fraud Class Action Deadline is Approaching for Investors \u2013 Contact BFA Law before December 15",
      "url": "https://www.globenewswire.com/news-release/2025/12/13/3204966/0/en/MLTX-FRAUD-UPDATE-Important-MoonLake-Immunotherapeutics-Securities-Fraud-Class-Action-Deadline-is-Approaching-for-Investors-Contact-BFA-Law-before-December-15.html",
      "time_published": "20251213T071800",
      "authors": [],
      "summary": "Bleichmar Fonti & Auld LLP has filed a securities fraud lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) and its executives. The lawsuit alleges that MoonLake misrepresented the superiority of its sonelokimab (SLK) drug, leading investors to believe it had a better clinical benefit and higher chances of regulatory approval. After disappointing Phase 3 trial results were announced on September 28, 2025, MoonLake's stock price plummeted by nearly 90%.",
      "banner_image": "https://ml.globenewswire.com/media/ZWQyNjkwMDgtMGEwNi00MDA3LWIzNjUtMzNlZmVjODc2MjBlLTEzMDI1NDUtMjAyNS0xMi0xMy1lbg==/tiny/Bleichmar-Fonti-Auld.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.926072"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.829703"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.747211"
        }
      ],
      "overall_sentiment_score": -0.607985,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.633012",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit",
      "url": "https://aijourn.com/deadline-soon-moonlake-immunotherapeutics-mltx-investors-who-lost-money-urged-to-contact-the-law-offices-of-frank-r-cruz-about-securities-fraud-lawsuit/",
      "time_published": "20251213T020951",
      "authors": [
        "Business Wire"
      ],
      "summary": "The Law Offices of Frank R. Cruz reminds MoonLake Immunotherapeutics (MLTX) investors of the December 15, 2025, deadline to act as lead plaintiff in a securities fraud class action lawsuit. This follows a significant stock drop after disappointing Phase 3 results for its drug candidate, sonelokimab (SLK), which allegedly failed to meet efficacy expectations compared to a competitor. The lawsuit claims that MoonLake made misleading statements regarding SLK's purported superiority.",
      "banner_image": "https://mms.businesswire.com/media/20251212167512/en/765953/22/Close_Up_Logo_HD_Blue.jpg",
      "source": "The AI Journal",
      "category_within_source": "General",
      "source_domain": "The AI Journal",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.941003"
        },
        {
          "topic": "finance",
          "relevance_score": "0.743864"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.603309"
        }
      ],
      "overall_sentiment_score": -0.82938,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.804598",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MLTX COURT ALERT: MoonLake Immunotherapeutics Securities Fraud Class Action is Ongoing - Investors with Losses Alerted to Contact BFA Law by December 15",
      "url": "https://fox40.com/business/press-releases/accesswire/1116186/mltx-court-alert-moonlake-immunotherapeutics-securities-fraud-class-action-is-ongoing-investors-with-losses-alerted-to-contact-bfa-law-by-december-15",
      "time_published": "20251212T200951",
      "authors": [
        "NULL"
      ],
      "summary": "A securities fraud class action lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ:MLTX) and its executives for potential violations of federal securities laws. The lawsuit alleges that the company misrepresented the superiority of its sonelokimab (SLK) treatment, which failed to meet its primary endpoint in Phase 3 trials, leading to a significant stock price drop. Investors who suffered losses are encouraged to contact Bleichmar Fonti & Auld LLP by December 15, 2025, to discuss their legal options.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1116186",
      "source": "FOX40 News",
      "category_within_source": "General",
      "source_domain": "FOX40 News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.817384"
        }
      ],
      "overall_sentiment_score": -0.915911,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.919835",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MoonLake Immunotherapeutics Class Action: Levi & Korsinsky Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX",
      "url": "https://fox4kc.com/business/press-releases/cision/20251212NY45116/moonlake-immunotherapeutics-class-action-levi-korsinsky-reminds-moonlake-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-december-15-2025-mltx",
      "time_published": "20251212T140951",
      "authors": [
        "NULL"
      ],
      "summary": "Levi & Korsinsky, LLP has notified investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit. The lawsuit alleges that MoonLake made false statements and concealed information about its drug candidate, SLK, specifically regarding its purported superiority over BIMZELX. Affected investors have until December 15, 2025, to request to be appointed as lead plaintiff.",
      "banner_image": "https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg?p=publish",
      "source": "FOX4KC.com",
      "category_within_source": "General",
      "source_domain": "FOX4KC.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.947715"
        },
        {
          "topic": "finance",
          "relevance_score": "0.739131"
        }
      ],
      "overall_sentiment_score": -0.805975,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.807414",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX",
      "url": "https://www.prnewswire.com/news-releases/moonlake-immunotherapeutics-class-action-the-gross-law-firm-reminds-moonlake-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-december-15-2025--mltx-302638589.html",
      "time_published": "20251212T110952",
      "authors": [
        "NULL"
      ],
      "summary": "The Gross Law Firm is reminding investors of MoonLake Immunotherapeutics (NASDAQ: MLTX) about a pending class action lawsuit with a lead plaintiff deadline of December 15, 2025. The lawsuit alleges that MoonLake Immunotherapeutics made materially false and/or misleading statements regarding its sole drug candidate, SLK, specifically concerning its purported superiority over BIMZELX. Shareholders who purchased MLTX shares between March 10, 2024, and September 29, 2025, are encouraged to contact the firm regarding potential lead plaintiff appointment.",
      "banner_image": "https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg?w=300",
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.827204"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.933385"
        }
      ],
      "overall_sentiment_score": -0.363611,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.407970",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.616829",
          "ticker_sentiment_score": "-0.342796",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "MLTX Stockholders Have Opportunity to Lead MoonLake Immunotherapeutics Class Action Lawsuit \u2013 Contact Bronstein, Gewirtz and Grossman, LLC Today!",
      "url": "https://www.cbs42.com/business/press-releases/accesswire/1087816/mltx-stockholders-have-opportunity-to-lead-moonlake-immunotherapeutics-class-action-lawsuit-contact-bronstein-gewirtz-and-grossman-llc-today",
      "time_published": "20251212T110951",
      "authors": [
        "NULL"
      ],
      "summary": "Bronstein, Gewirtz & Grossman, LLC has notified investors of a class action lawsuit filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and its officers. The lawsuit alleges that MoonLake misrepresented the efficacy of its drug candidate, sonelokimab (SLK), leading to significant investor damages when the drug's shortcomings were revealed. Investors who purchased MoonLake securities between March 10, 2024, and September 29, 2025, are encouraged to contact the firm to potentially serve as lead plaintiff.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/a94dabec-ac41-4852-a687-1ce00f6ce824/1087816/bronsteinlogonew.jpg",
      "source": "CBS 42",
      "category_within_source": "General",
      "source_domain": "CBS 42",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.943596"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.819362"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.724425"
        }
      ],
      "overall_sentiment_score": -0.922862,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.910819",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX",
      "url": "https://www.morningstar.com/news/pr-newswire/20251211ny44168/moonlake-immunotherapeutics-class-action-the-gross-law-firm-reminds-moonlake-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-december-15-2025-mltx",
      "time_published": "20251212T110912",
      "authors": [
        "NULL"
      ],
      "summary": "The Gross Law Firm has issued a notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding a pending class action lawsuit. Shareholders who purchased MLTX shares between March 10, 2024, and September 29, 2025, are encouraged to contact the firm, as the complaint alleges the company made materially false or misleading statements about its drug candidate SLK. The deadline to seek lead plaintiff appointment in this class action is December 15, 2025.",
      "banner_image": "NULL",
      "source": "Morningstar",
      "category_within_source": "General",
      "source_domain": "Morningstar",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.846046"
        },
        {
          "topic": "finance",
          "relevance_score": "0.713827"
        }
      ],
      "overall_sentiment_score": -0.404843,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MLTX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.409861",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    }
  ]
}